Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · IEX Real-Time Price · USD
5.01
-0.13 (-2.53%)
At close: Dec 29, 2023, 4:00 PM
4.93
-0.08 (-1.60%)
After-hours: Dec 29, 2023, 7:45 PM EST
Abeona Therapeutics Revenue
Abeona Therapeutics had revenue of $3.57M in the twelve months ending September 30, 2023, down -17.90% year-over-year. In the year 2022, Abeona Therapeutics had annual revenue of $1.41M, a decrease of -52.87%.
Revenue (ttm)
$3.57M
Revenue Growth
-17.90%
P/S Ratio
34.79
Revenue / Employee
$62,596
Employees
57
Market Cap
124.11M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
Dec 31, 2020 | 10.00M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 3.00M | 2.16M | 258.18% |
Dec 31, 2017 | 837.00K | -52.00K | -5.85% |
Dec 31, 2016 | 889.00K | -151.00K | -14.52% |
Dec 31, 2015 | 1.04M | 115.00K | 12.43% |
Dec 31, 2014 | 925.00K | -1.12M | -54.70% |
Dec 31, 2013 | 2.04M | -2.36M | -53.63% |
Dec 31, 2012 | 4.40M | 2.54M | 135.63% |
Dec 31, 2011 | 1.87M | 1.34M | 251.98% |
Dec 31, 2010 | 531.00K | 179.00K | 50.85% |
Dec 31, 2009 | 352.00K | 61.00K | 20.96% |
Dec 31, 2008 | 291.00K | 234.00K | 410.53% |
Dec 31, 2007 | 57.00K | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 1.15M | 904.00K | 372.02% |
Dec 31, 2001 | 243.00K | 136.00K | 127.10% |
Dec 31, 2000 | 107.00K | 92.00K | 613.33% |
Dec 31, 1999 | 15.00K | - | - |
Dec 31, 1998 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.06B |
Emergent BioSolutions | 1.10B |
High Tide | 468.81M |
Inogen | 327.86M |
FONAR | 101.29M |
Seer, Inc. | 16.83M |
Sagimet Biosciences | 2.00M |
ABEO News
- 16 days ago - Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) - GlobeNewsWire
- 6 weeks ago - Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments - GlobeNewsWire
- 3 months ago - Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 3 months ago - Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer - GlobeNewsWire
- 4 months ago - Abeona Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission - GlobeNewsWire
- 5 months ago - Abeona Therapeutics Reports Second Quarter 2023 Financial Results - GlobeNewsWire